Fig. 2From: Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in JapanRelationship between serum concentrations of biomarkers at baseline and the efficacy of pirfenidone on changes in vital capacity from baseline. All patients were dichotomized by the median concentration of a SP-D, b SP-A and c KL-6 at baseline to the high and low biomarker subgroups. Blue lines, pirfenidone; black lines, placebo. Mean ± SE. Mean changes were calculated with the mixed model for repeated measurement (MMRM). *p < 0.05, **p < 0.01Back to article page